Westerkirk Capital’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$102K Hold
2,128
0.01% 210
2026
Q1
$78.2K Hold
2,128
0.01% 206
2025
Q4
$108K Sell
2,128
-2,472
-54% -$126K 0.01% 216
2025
Q3
$255K Buy
+4,600
New +$269K 0.03% 217

Other funds holding NVO

Westerkirk Capital's NVO Position: Q2 2026 in Review

Westerkirk Capital held its Novo Nordisk (NVO) position steady in Q2 2026 at 2,128 shares worth $102K. The position accounts for 0.01% of the portfolio, ranked #210.

Westerkirk Capital first reported a position in NVO in Q3 2025 and has held it in 4 quarters since. The position peaked at $255K in Q3 2025. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Westerkirk Capital held 2,128 shares of Novo Nordisk worth $102K as of Q2 2026.
  • Westerkirk Capital left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.01% of Westerkirk Capital's portfolio in Q2 2026, its #210 holding.
  • Westerkirk Capital first reported a position in Novo Nordisk in Q3 2025 and has held it in 4 quarters since.
  • Westerkirk Capital's Novo Nordisk position peaked at $255K in Q3 2025.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Westerkirk Capital's 13F filing for Q2 2026, filed 10 Aug 2026.